This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
Study estimates 1 in 7 Medicare beneficiaries with high BMI may qualify for anti-obesity drug
A new study led by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham health care system, estimates that 3.6 million Medicare beneficiaries are most likely to become eligible for semaglutide.
If Medicare Part D narrowly defines cardiovascular disease, the majority of patients would remain ineligible, while new federal spending could still exceed $10 billion.
Current federal regulation restricts Medicare from covering drugs prescribed solely for weight loss. However, in March 2024, Medicare announced it would extend coverage to semaglutide (Wegovy), a popular glucagon-like peptide-1 receptor agonist (GLP-1RA), for patients with elevated body mass index (BMI) who also had established cardiovascular disease (CVD).
This means that the definition of "established CVD," which has not been formally codified, will have outsized impacts on both public health and Medicare costs.
The study also estimates eligibility and associated maximum costs if different definitions of cardiovascular risk were to be considered. The findings are published in the Annals of Internal Medicine.
The research team analyzed data from respondents over 65 or who were on Medicare and who took part in the National Health and Nutrition Examination Survey (NHANES) between 2011 and 2020. They found that if all patients with elevated BMI and a history of heart attack, stroke, coronary artery disease, or angina were treated with semaglutide, maximum annual costs to Medicare could be as high as $34.3 billion after rebates.
"When established cardiovascular disease is narrowly defined, only 1 in 7 Medicare beneficiaries with elevated BMI are likely to be eligible to receive semaglutide, but costs to Medicare could still exceed $10 billion per year," said lead author Alexander Chaitoff, MD, MPH, of the Center for Health care Delivery Sciences in the Division of Pharmacoepidemiology at BWH.
"In this conservative coverage scenario, that means most beneficiaries with elevated BMI and cardiovascular risk would remain ineligible for semaglutide, yet the medication could still potentially become one of the costliest drugs for Medicare."
More information: Estimating New Eligibility and Maximum Costs of Expanded Medicare Coverage of Semaglutide for Cardiovascular Risk Prevention, Annals of Internal Medicine (2024). DOI: 10.7326/ANNALS-24-00308
